Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. A
A logo

A Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
116.560
Open
115.580
VWAP
115.32
Vol
738.75K
Mkt Cap
32.62B
Low
114.160
Amount
85.19M
EV/EBITDA(TTM)
18.60
Total Shares
282.60M
EV
34.22B
EV/OCF(TTM)
24.51
P/S(TTM)
4.65
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Show More

Events Timeline

(ET)
2026-03-09
05:20:00
Agilent Acquires Biocare Medical for $950M
select
2026-02-25 (ET)
2026-02-25
16:20:00
Agilent Reports Q1 Revenue of $1.80B, Slightly Below Consensus
select
2026-02-25
16:20:00
Raises FY26 Revenue Outlook to $7.3B-$7.5B
select

News

seekingalpha
8.5
03-09seekingalpha
PinnedAgilent to Acquire Biocare Medical for $950 Million
  • Acquisition Overview: Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical for $950 million in cash, a deal expected to enhance Agilent's revenue growth rate and margin profile.
  • Biocare's Performance: Since 2021, Biocare has achieved annual double-digit revenue and profit growth, generating over $90 million in revenue in 2025, bolstered by more than 300 specialized antibodies and strong R&D capabilities, thereby enhancing Agilent's pathology portfolio.
  • Strategic Importance: Agilent's President and CEO Padraig McDonnell stated that this acquisition reflects the company's strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation, further solidifying its position in the life sciences and diagnostics markets.
  • Transaction Timeline: The deal is expected to close by no later than Agilent's fourth fiscal quarter of 2026, at which point Biocare will become part of Agilent's Life Sciences and Diagnostics Markets Group, supporting the company's future business expansion.
Newsfilter
7.5
12:40 PMNewsfilter
Agilent Launches Advanced Therapeutics CDMO Solution
  • Integrated Manufacturing Capabilities: Agilent's launch of the Advanced Therapeutics solution combines the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado, offering a comprehensive suite of customizable manufacturing services that enhance the company's competitiveness in the biopharmaceutical sector.
  • Diverse Product Portfolio: The CDMO portfolio includes oligonucleotides, microbial fermentation, complex synthetic chemistry, highly potent APIs, and cell line development, catering to diverse client needs in clinical and commercial-scale production, thereby driving business growth.
  • Enhanced Customer Experience: By providing a streamlined, end-to-end service from discovery to clinical and commercial-scale manufacturing, Agilent creates a more integrated experience for clients, deepening technical partnerships and building customer trust.
  • Long-Term Commitment: Agilent's CEO Padraig McDonnell emphasizes that this launch reflects the company's long-term commitment to growth, investment, and leadership in the industry, aimed at supporting clients in developing life-changing therapies.
Benzinga
8.5
03-09Benzinga
Agilent Acquires Biocare Medical for $950 Million
  • Acquisition Overview: Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million, with the deal expected to close in the fourth fiscal quarter of 2026, enhancing its market position in pathology.
  • Growth Potential: Biocare Medical boasts over 300 specialized antibodies and strong R&D capabilities, achieving double-digit revenue and profit growth since 2021, which is anticipated to significantly boost Agilent's revenue growth and margins.
  • Market Integration Impact: The acquisition will integrate Biocare's product portfolio into Agilent's Life Sciences and Diagnostics Markets Group, expected to enhance its ability to develop and commercialize new IVD antibodies, thereby expanding its reach across clinical and research pathology labs.
  • Stock Performance Analysis: Despite a 5.60% decline in Agilent's stock over the past 12 months, currently trading at $116.41, below its 20-day and 50-day SMAs, the strategic acquisition of Biocare may improve its market performance in the future.
stocktwits
8.5
03-09stocktwits
Agilent Acquires Biocare to Enhance Pathology Portfolio
  • Biocare Acquisition: Agilent's $950 million acquisition of Biocare adds over 300 specialized antibodies and R&D capabilities, yet failed to revive investor sentiment, with shares slipping nearly 1% amid a broader market selloff.
  • Financial Impact: Agilent anticipates that the acquisition will boost revenue growth and margins in the first year, with earnings per share expected to increase approximately 12 months post-closing, indicating strong long-term growth potential.
  • Market Reaction: Agilent's Q1 earnings report showed $1.36 per share on $1.80 billion revenue, slightly below analyst expectations, prompting several brokerages to cut price targets while most maintained positive ratings on the stock.
  • Retail Sentiment: Despite a 15% decline in stock price year-to-date, retail sentiment on Stocktwits remains 'bullish', reflecting confidence in Agilent's long-term prospects.
Newsfilter
8.5
03-09Newsfilter
Agilent Acquires Biocare Medical to Enhance Pathology Portfolio
  • Acquisition Scale: Agilent has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, for $950 million, a transaction expected to significantly enhance Agilent's revenue and profit growth.
  • Growth Potential: Biocare has achieved annual double-digit revenue and profit growth since 2021, with projected revenues exceeding $90 million in 2025, and the acquisition will further strengthen Agilent's competitive position in the pathology market.
  • Strategic Synergies: This acquisition will integrate Agilent's global operations with Biocare's strong U.S. commercial presence, creating a more robust platform to meet diverse research and clinical customer needs while accelerating new product development.
  • Financial Benefit Expectations: The transaction is expected to positively impact Agilent's top-line growth rate, margin profile, and non-instrument revenue mix in the first year, with an anticipated accretive effect on earnings per share approximately 12 months post-close.
Newsfilter
8.5
03-09Newsfilter
Agilent to Acquire Biocare for $950 Million
  • Acquisition Overview: Agilent Technologies has announced its acquisition of Biocare for $950 million in cash, marking a strategic expansion in the life sciences and diagnostics sector, which is expected to enhance its competitiveness in the cancer diagnostics market.
  • Biocare's Growth Journey: Under the stewardship of Excellere Partners and GHO Capital, Biocare has achieved annual double-digit revenue and profit growth since 2021, strengthening its core immunohistochemistry business while expanding into molecular diagnostics, showcasing its strong market potential.
  • Strategic Synergies: This acquisition will enable Biocare to complement Agilent's capabilities, with both companies' expertise in cancer diagnostics fostering innovation and improved service levels, ultimately providing higher quality solutions for customers.
  • Future Outlook: Biocare's CEO, Luis de Luzuriaga, stated that the acquisition will accelerate the company's innovation process and enhance service quality, ultimately benefiting patients, reflecting a shared commitment to product quality and clinical impact between the two organizations.
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
Wall Street analysts forecast A stock price to rise
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
160.00
Averages
171.67
High
180.00
Current: 0.000
sliders
Low
160.00
Averages
171.67
High
180.00
Citi
Buy
maintain
$185
AI Analysis
2026-03-11
New
Reason
Citi
Price Target
$185
AI Analysis
2026-03-11
New
maintain
Buy
Reason
Citi opened an "upside 90-day catalyst watch" on shares of Agilent while keeping a Buy rating on the name with a $185 price target. The share overhang of a potential transformational acquisition should be removed with Agilent's deal for Biocare Medical, the analyst tells investors in a research note. Citi sees the stock's multiple rebounding.
Morgan Stanley
Kallum Titchmarsh
Overweight
downgrade
$180 -> $160
2026-03-03
Reason
Morgan Stanley
Kallum Titchmarsh
Price Target
$180 -> $160
2026-03-03
downgrade
Overweight
Reason
Morgan Stanley analyst Kallum Titchmarsh lowered the firm's price target on Agilent to $160 from $180 and keeps an Overweight rating on the shares. The firm updated its model following fiscal Q1 results.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for A
Unlock Now

Valuation Metrics

The current forward P/E ratio for Agilent Technologies Inc (A.N) is 23.19, compared to its 5-year average forward P/E of 25.43. For a more detailed relative valuation and DCF analysis to assess Agilent Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.43
Current PE
23.19
Overvalued PE
29.67
Undervalued PE
21.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.70
Current EV/EBITDA
19.36
Overvalued EV/EBITDA
23.84
Undervalued EV/EBITDA
17.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.82
Current PS
5.32
Overvalued PS
6.59
Undervalued PS
5.05

Financials

AI Analysis
Annual
Quarterly

Whales Holding A

X
XTX Markets Limited
Holding
A
+15.24%
3M Return
S
Schonfeld Strategic Advisors LLC
Holding
A
+12.86%
3M Return
C
Campbell & Company, LP
Holding
A
+10.02%
3M Return
P
Pacific Heights Asset Management, LLC
Holding
A
+9.97%
3M Return
L
Liontrust Asset Management PLC
Holding
A
+8.29%
3M Return
R
RobecoSAM AG
Holding
A
+7.24%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Agilent Technologies Inc (A) stock price today?

The current price of A is 115.24 USD — it has decreased -0.16

What is Agilent Technologies Inc (A)'s business?

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

What is the price predicton of A Stock?

Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is171.67 USD with a low forecast of 160.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Agilent Technologies Inc (A)'s revenue for the last quarter?

Agilent Technologies Inc revenue for the last quarter amounts to 1.80B USD, increased 6.96

What is Agilent Technologies Inc (A)'s earnings per share (EPS) for the last quarter?

Agilent Technologies Inc. EPS for the last quarter amounts to 1.07 USD, decreased -3.60

How many employees does Agilent Technologies Inc (A). have?

Agilent Technologies Inc (A) has 18100 emplpoyees as of March 11 2026.

What is Agilent Technologies Inc (A) market cap?

Today A has the market capitalization of 32.62B USD.